EntreMed has initiated Phase II trials of its drug candidate ENMD 2076 for patients with platinum-resistant ovarian cancer.
The trials will be conducted in six clinical centres in the US and Canada after no objection letter was received from the Therapeutic Products Directorate of Health Canada to conduct the studies.
The first site for the study will be the Princess Margaret Hospital, University of Toronto, with additional sites due to begin the trials in the second quarter this year.
The 60-patient study will aim to determine the progression-free survival rate over six months.
ENMD-2076 had previously been awarded orphan drug designation in the US and is currently in three Phase I studies in solid tumours, multiple myeloma and leukaemia.